Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-12. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0000947871-26-000784
acquired disposedA
codeP
direct or indirectI
form4
is derivativefalse
issuer nameBlossomHill Therapeutics, Inc.
labelOpen market purchase
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0000947871-26-000784",
"acquired_disposed": "A",
"code": "P",
"direct_or_indirect": "I",
"form": "4",
"is_derivative": false,
"issuer_name": "BlossomHill Therapeutics, Inc.",
"label": "Open market purchase",
"person_name": "OrbiMed Capital GP VIII LLC",
"price": 16,
"role": "Director",
"security": "Common Stock",
"shares": 625000,
"shares_owned_after": 2714279,
"source_path": "edgar/data/1839970/0000947871-26-000784.txt",
"ticker": "BLSM",
"transaction_date": "2026-08-10",
"value": 10000000
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.